Effects of Different Doses of Glucosyl-Hesperidin CITRAPEAK on Exercise Performance, Recovery, Blood Flow, Mood, and Cognitive Function in Healthy Adults Aged 18 to 50

What this Trial Is About

Researchers are examining how different doses of glucosyl-hesperidin CITRAPEAK affect exercise performance, recovery, blood flow, cognitive function, mood, sleep, and fuel use in healthy, recreationally active adults aged 18 to 50. This randomized, double-blind, placebo-controlled study aims to understand dose-dependent effects in this population to support cardiovascular and cognitive health improvements. Participants will be randomly assigned to one of three groups a placebo group receiving a daily 400 mg cellulose supplement a group receiving 200 mg glucosyl-hesperidin plus 200 mg cellulose daily or a group receiving 400 mg glucosyl-hesperidin daily. The study lasts 8 weeks, with daily supplement intake monitored through logs. The design includes multiple visits with various assessments, including exercise testing, blood flow measurements, and cognitive evaluations. During the study, participants will undergo tests such as peak VO2 and Wingate anaerobic power assessments, blood flow analysis at multiple times post-supplement intake, and mood and sleep quality questionnaires. Researchers will track adherence via supplementation logs and measure changes in physical and cognitive performance, mood, sleep, and nitric oxide levels. Participation spans the full 8-week supplementation period with evaluations at baseline and week 8.

Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators